ICPT
- Intercept Pharmaceuticals, Inc.
()
Overview
Company Summary
Intercept Pharmaceuticals, Inc. (ICPT) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases. The company's primary focus is on non-viral liver diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
Intercept Pharmaceuticals is renowned for developing Ocaliva (obeticholic acid), which is the first and currently the only approved drug for the treatment of PBC. The company is also actively working on developing treatments for other liver diseases.
NASH, one of their key areas of focus, is a progressive liver disease characterized by the buildup of fat in the liver, inflammation, and damage. It is often associated with obesity, diabetes, and metabolic syndrome. Intercept is conducting research and clinical trials to develop effective therapies for NASH, as it is a severe and largely unmet medical need.
In addition to their product development efforts, Intercept Pharmaceuticals is engaged in partnerships and collaborations with other pharmaceutical companies and research institutions to expand their knowledge base and explore innovative approaches to liver disease treatments.
Overall, Intercept Pharmaceuticals is dedicated to improving the lives of patients suffering from various liver diseases by developing novel therapies that target the underlying causes of these conditions.